Biomea Fusion, Inc. Stock Price, News & Analysis

Biomea Fusion, Inc. (Nasdaq: BMEA) presented promising data for its covalent menin inhibitor, BMF-219, at the AACR Annual Meeting. The drug showed significant cytotoxic activity in various preclinical models, including diffuse large B-cell lymphoma and multiple myeloma. BMF-219 demonstrated superior potency compared to existing KRAS inhibitors, achieving over 90% growth inhibition in multiple cell lines. A Phase I study (COVALENT-101) is currently enrolling patients with relapsed/refractory cancers, indicating potential for treating significant unmet needs in oncology.

Biomea Fusion (Nasdaq: BMEA) announced acceptance of a late-breaking abstract detailing preclinical data from an in vivo study of BMF-219, aimed at treating type 2 diabetes, for presentation at the American Diabetes Association's 82nd Scientific Sessions, taking place June 3-7, 2022, in New Orleans. The company focuses on developing covalent small molecules for genetically defined cancers and metabolic diseases, which may offer advantages over conventional drugs. Further details on the presentation will be disclosed following ADA's embargo policies.

Biomea Fusion, a clinical-stage biopharmaceutical company, announced its participation in the Oppenheimer 32nd Annual Virtual Healthcare Conference on March 16, 2022. CEO Thomas Butler will engage in a fireside chat at 7:00 AM Pacific Time. The company focuses on developing novel irreversible covalent small molecules aimed at treating genetically defined cancers and metabolic diseases. They utilize their proprietary FUSION™ System to advance therapeutic agents targeting key oncogenic drivers.

Investors can access the audio webcast on the company's website in the Investor Relations section.

Biomea Fusion announced the acceptance of its abstract for presentation at the upcoming American Diabetes Association Scientific Sessions, scheduled for June 3-7, 2022. The presentation will focus on preclinical data for BMF-219, a novel treatment for type 2 diabetes. The company plans to initiate a Phase I/II clinical trial of BMF-219 in the second half of 2022, pending IND application clearance. Biomea aims to develop irreversible small molecules to treat genetically defined cancers and metabolic diseases, and sees significant potential in BMF-219 as an oral treatment for diabetes.

Biomea Fusion announced promising preclinical results for its lead program, BMF-219, an irreversible covalent menin inhibitor, at the AACR Annual Meeting 2022. The data showed high potency and complete growth inhibition in high-grade B-cell lymphoma and multiple myeloma patient-derived models. BMF-219 also demonstrated strong efficacy in various KRAS-mutant cancers, showcasing advantages over the KRAS-targeted inhibitor sotorasib. Biomea plans to enroll patients in clinical trials for multiple myeloma and diffuse large B-cell lymphoma in 2022, with an IND submission for KRAS-mutant tumors anticipated by Q4 2022.

Biomea Fusion (BMEA) reported a net loss of $41.6 million for 2021, significantly up from $5.3 million in 2020, driven by increased R&D and G&A expenses. Research and development expenses soared to $28.0 million, primarily due to costs associated with BMF-219, an irreversible covalent menin inhibitor currently in a Phase I trial. The company plans to expand trials for BMF-219 into seven cancers and diabetes, anticipating a second clinical candidate announcement in mid-2022. As of year-end 2021, cash and equivalents totaled $175.7 million, supporting future initiatives.

Biomea Fusion has appointed Dr. Steve Morris as Chief Medical Officer, who previously served as a consultant since 2020. He will lead the clinical development of BMF-219, an irreversible covalent menin inhibitor currently in a Phase I trial aimed at treating patients with specific acute leukemias. Biomea plans to expand clinical studies for BMF-219 into seven tumor types and diabetes. Dr. Morris' extensive research background includes significant contributions to the understanding of oncogenes like ALK, enhancing the company's clinical prospects in oncology.

Biomea Fusion (Nasdaq: BMEA) has initiated a Phase I clinical trial for BMF-219, the first irreversible covalent menin inhibitor aimed at treating relapsed/refractory acute leukemias. The trial involves enrolling patients with MLL1/KMT2A gene rearrangements or NPM1 mutations across 20 clinical sites in the U.S. This milestone marks Biomea's transition to a clinical stage company, with expectations for further pipeline candidates to be announced soon. Biomea aims to leverage its FUSION™ System for developing targeted therapies in oncology and metabolic diseases.

Biomea Fusion (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, announced its participation at the H.C. Wainwright BioConnect Conference held from January 10-13, 2022. CEO Thomas Butler will provide a corporate update during a fireside chat. The company is focused on developing irreversible small molecules for treating genetically defined cancers and metabolic diseases, utilizing its proprietary FUSION™ discovery platform. This innovative approach aims to offer significant advantages in drug efficacy and patient outcomes.